Journal of Clinical Oncology
Articles in this Issue
Phase 2 trial of immuno-ablation with intrabladder injection of N-803 or intravesical N-803 plus BCG for intermediate-risk non-muscle invasive papillary bladder cancer.
TPS905 Background: Response rates (55-65%) with bacillus Calmette-Guerin (BCG) monotherapy in papillary non-muscle invasive bladder cancer (NMIBC) are low...
Assessing global disparities in clinical trial availability for renal cell carcinoma (RCC).
449 Background: Clinical trials are the cornerstone for developing novel therapies and diagnostic tools. Due to advancemen...
Transcriptional profiling of patients with metastatic hormone-sensitive prostate cancer to uncover specific signatures linked to the transition from androgen-dependent to androgen-independent phenotype.
227 Background: Metastatic hormone-sensitive prostate cancers (mHSPC) are generally sensitive to androgen deprivation therapy (ADT). However, resistance o...
Utilization, healthcare expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States.
370 Background: Radical prostatectomy (RP) and radiotherapy are standard-of-care treatments for localized prostate cancer. We studied the contemporary tre...
Presurgical treatment for inferior vena cava tumor thrombus in patients with renal cell carcinoma: A scoping review.
602 Background: To date, there is no evidence-based standard of care for the management of patients with tumor-related thrombus (TT) in the inferior vena...
Survival outcomes among metastatic castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitor and docetaxel.
57 Background: Real-world evidence on treatment patterns and real-world overall survival (rwOS) are limited in metastatic castration-resistant prostate ca...
Boosting survival in advanced urothelial carcinoma: The power of CBM588 probiotic and pembrolizumab combination.
774 Background: Immune checkpoint inhibitors (ICIs) is now standard cares for locally advanced or metastatic Urothelial Carcinoma (UC). One of the probiot...
Validation of new prognostic factors for relapse in patients with clinical stage I seminoma.
625 Background: Patients with clinical stage I (cSI) seminomatous testicular germ cell tumors (GCT) have a relapse risk of 5 - 30% under surveillance afte...
Interpretable machine learning for prostate biopsy: Cohort study.
333 Background: The objective of this study is to develop prediction models and provide diagnostic results for prostate biopsy among patients....
Serum biomarkers in metastatic castration-resistant prostate cancer (mCRPC) patients receiving [ <sup>177</sup> Lu]Lu-PSMA-617 therapy: Post hoc analysis of a phase II clinical trial.
190 Background: [ 177 Lu]Lu-PSMA-617 ( 177 Lu-PSMA-617) has been recently approved for metastatic castrati...
Association between vascular patterns of clear cell renal cell carcinoma and immune cell infiltration and therapeutic response.
575 Background: Clear cell renal cell carcinoma (ccRCC) is a highly vascularized tumor with histological heterogenous appearance. We explored whether vasc...
Systemic therapy clinical trial participation in patients with bladder and kidney cancers.
451 Background: Patient participation in clinical trials has led to numerous treatment advances in renal cell carcinoma (RCC) and urothelial carcinoma (UC...
Treatment of low-grade intermediate-risk non-muscle-invasive bladder cancer with UGN-102: Results of the phase 3 ATLAS and ENVISION studies.
777 Background: The ATLAS and ENVISION phase 3 studies (NCT04688931/NCT05243550) treated patients with low-grade intermediate-risk non-muscle-invasive bla...
Application of canary histology classifier in prostate biopsies for risk stratification.
412 Background: Nguyen et al recently proposed an outcome-based radical prostatectomy (RP) histologic classifier (PMID 38828674, “...
A prospective, single-center, single-arm clinical study of adjuvant toripalimab combined with axitinib in non-clear renal cell carcinoma (nccRCC) patients with high-risk recurrence factors (IUNU-RC-102).
TPS613 Background: Non-clear cell renal cell carcinoma (nccRCC) accounts for approximately 25–30% of all renal cell carcinoma (RCC) cases and is associate...
Automated risk stratification in localized prostate cancer using an AI-assisted framework.
341 Background: Specialist clinicians (oncologists, urologists, radiation oncologists) read through free text reports of prostate MRI and biopsy reports t...
Computational pathology–based classifier for predicting Gleason grade group upgrading on radical prostatectomy from diagnostic biopsies.
329 Background: Prostate biopsy is the gold standard for diagnosing and risk stratification of prostate cancer. As therapeutic options expand, detailed bi...
Genome-scale metabolic reconstruction of urinary microbiome: Pathway for personalized medicine.
822 Background: The human microbiome significantly influences the efficacy and safety of various medications. To integrate microbial metabolism into preci...
Neoadjuvant pembrolizumab (pembro) and accelerated methotrexate, vinblastine, doxorubicin, cisplatin (aMVAC) in non-urothelial (non-UC) histologic subtype muscle invasive bladder cancer (MIBC): A phase 2 trial.
769 Background: Cisplatin-based chemotherapy (CT) prior to radical cystectomy (RC) + perioperative anti-PDL1 improves pathologic complete response rates (...
First preliminary results of artificial intelligence-generated, explainable treatment recommendations for renal cell cancer based on multidisciplinary cancer conferences.
465 Background: The expert panel in multidisciplinary cancer conferences (MCC) decides on the best available treatment for the individual cancer patient....
Investigating clinical associations between genomic alterations and prostate cancer lineage states using circulating tumor cell RNA sequencing.
256 Background: Resistance to Androgen Receptor Pathway Inhibitors (ARPI) in metastatic prostate cancer (mPC) is universal and can be driven by complex ge...
Safety of combining radiotherapy and antibody drug conjugates in advanced urothelial and other cancers.
758 Background: Antibody drug conjugates (ADCs) such as enfortumab vedotin (EV) and sacituzumab govitecan (SG) are novel treatments increasingly used for...
Choice of androgen receptor pathway inhibitors (ARPi) by disease volume and timing of metastases in metastatic hormone sensitive prostate cancer (mHSPC).
184 Background: We update evidence on mHSPC when new evidence becomes available (PMID: 36862387). ARANOTE trial prompted us to assess the comparative effi...
A comprehensive evaluation of gene expression-based signatures for detecting tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC).
591 Background: TLS are organized lymphoid aggregates linked to improved response to immunotherapy in multiple cancers, including mRCC. Traditionally, TLS...
Upstaging and risk migration with blue light cystoscopy for non–muscle-invasive bladder cancer: Results from a prospective multi-center registry.
686 Background: Blue-light cystoscopy (BLC) is an established procedure for use in the diagnosis and surveillance of patients with non-muscle-invasive bla...